Xing Liu

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma

Jing-jing Zhao, Furong Huang, Xiao-shi Zhang, 2021, Journal of Cancer Research and Clinical Oncology.

Adjuvant PD‐1 inhibitor versus high‐dose interferon α‐2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis

Xiaoshi Zhang, D. Li, Jing-jing Li, 2021, Dermatologic therapy.

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study

Xiaojun Wu, Hui-shan Lu, Hui Wu, 2023, Translational oncology.

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study

Xiao-shi Zhang, D. Weng, D. Li, 2021, Frontiers in Oncology.

Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.

Xiaoshi Zhang, D. Li, Jing-jing Li, 2021 .